Anthony James Culverwell

CIK: 0001693548

Transaction Breakdown

Open Market Buys (P)2 (28.6%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (71.4%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

QNRX

Quoin Pharmaceuticals, Ltd.

Director

Discretionary Trading P&L

Holdings

Transaction History (7 total)

QNRX
Quoin Pharmaceuticals, Ltd.
Aug 31, 2026
Purchase(P)
Direct
6.1K shares at avg. $4.88$30K
QNRX
Quoin Pharmaceuticals, Ltd.
Aug 27, 2026
Award(A)
Direct
31.4K shares at avg. $5.15$161K
QNRX
Quoin Pharmaceuticals, Ltd.
Feb 4, 2026
Award(A)
Share Option (Right to Buy)
Direct
21.7K shares-
QNRX
Quoin Pharmaceuticals, Ltd.
Aug 21, 2025
Award(A)
Share Option (Right to Buy)
Direct
13.7K shares-
QNRX
Quoin Pharmaceuticals, Ltd.
May 29, 2025
Award(A)
Share Option (Right to Buy)
Direct
7.8K shares-
QNRX
Quoin Pharmaceuticals, Ltd.
Dec 23, 2024
Purchase(P)
Direct
100K shares at avg. $0.45$45K
QNRX
Quoin Pharmaceuticals, Ltd.
Dec 9, 2024
Award(A)
Share Option (Right to Buy)
Direct
50.7K shares-

		Type	Shares	Price		Ownership
Aug 31, 2026	QNRX Quoin Pharmaceuticals, Ltd.	Purchase(P)	6,146	$4.88	$29,992	Direct
Aug 27, 2026	QNRX Quoin Pharmaceuticals, Ltd.	Award(A)	31,352	$5.15	$161,463	Direct
Feb 4, 2026	QNRX Quoin Pharmaceuticals, Ltd.	Award(A) Share Option (Right to Buy)	21,709	-	-	Direct
Aug 21, 2025	QNRX Quoin Pharmaceuticals, Ltd.	Award(A) Share Option (Right to Buy)	13,682	-	-	Direct
May 29, 2025	QNRX Quoin Pharmaceuticals, Ltd.	Award(A) Share Option (Right to Buy)	7,760	-	-	Direct
Dec 23, 2024	QNRX Quoin Pharmaceuticals, Ltd.	Purchase(P)	100,000	$0.45	$45,000	Direct
Dec 9, 2024	QNRX Quoin Pharmaceuticals, Ltd.	Award(A) Share Option (Right to Buy)	50,714	-	-	Direct

1-7 of 7 transactions

About Culverwell Anthony James

Culverwell Anthony James (SEC CIK 0001693548) files insider reports with the SEC as Director of Quoin Pharmaceuticals, Ltd. (QNRX).

Signal8 holds 7 ownership filings by Culverwell Anthony James, all Form 4s, filed between Dec 10, 2024 and Sep 1, 2026. Those filings report 7 transactions, from Dec 9, 2024 to Aug 31, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Culverwell Anthony James's filings is in ASHBURN, VA.

Recent filings by Culverwell Anthony James

Aug 31, 2026: Open-market purchase of QNRX shares (Form 4, code P).
Aug 27, 2026: Grant or award of QNRX shares (Form 4, code A).
Feb 4, 2026: Grant or award of QNRX derivative securities (Form 4, code A).
Aug 21, 2025: Grant or award of QNRX derivative securities (Form 4, code A).
May 29, 2025: Grant or award of QNRX derivative securities (Form 4, code A).

Other insiders filing for Quoin Pharmaceuticals, Ltd. (QNRX)

LANGER DENNIS, Director
Carter Denise P., Chief Operating Officer
Myers Michael, Chief Executive Officer
Lawlor Sally Bridget, Chief Financial Officer
Cooper Joseph Patrick, Director
SEMBER MICHAEL T, Director

How to read Form 4 transaction codes